The MSO Cartel: Inside the Price-Fixing Lawsuit That Just Blew the Industry Open

For years, anyone who actually worked in cannabis knew the fix was in. Walk into a dispensary in Ohio, then walk into one in Pennsylvania, then one in New Jersey. Different state, different storefront, same five brands on the shelf. Same prices. Same promotions running the same week. Coincidence is the polite word for it. The word the Ohio Attorney General used in February was cartel.

On February 6, 2026, Ohio AG Dave Yost filed suit against nine of the largest multistate cannabis operators in America, alleging they conspired to fix prices, allocate shelf space, and squeeze small Ohio operators out of the market. The complaint reads like a federal antitrust filing dropped on a different industry by mistake. Except it isn't a mistake. It's the first time a state law enforcement officer has said in public, on the record, what every craft grower and every social equity licensee has been saying privately for half a decade.

This is the lawsuit. This is who got named. And this is why the cannabis industry is about to look very different.

What the Ohio Lawsuit Actually Alleges

The complaint, filed in Ohio state court, accuses nine publicly-traded MSOs of three specific anti-competitive behaviors.

The first is reciprocal supply agreements — companies agreeing to buy each other's products across state lines in exchange for shelf space. If you're an MSO with a license in Ohio and another in Florida, and a competitor has the same footprint reversed, you trade. Your products go on their shelves in Florida. Their products go on yours in Ohio. The independent grower who only operates in Ohio gets locked out, regardless of whether their flower is better or cheaper.

The second is information sharing. The lawsuit alleges these companies were trading "competitively sensitive non-public information" — pricing data, inventory levels, promotional calendars, expansion plans. In any other industry, that's an antitrust felony waiting to happen. In cannabis, it was Tuesday.

The third is discriminatory supply terms. The MSOs allegedly offered favorable wholesale pricing and promotional support to retailers who carried their products exclusively or near-exclusively, and unfavorable terms to retailers who tried to balance their menus with independent brands.

Yost's filing names a stark statistic: 13 of Ohio's 60 counties with cannabis retail have only MSO-owned stores. No independent operators. None. That isn't a market outcome. That's a market design.

The Nine Companies Named

The defendants in the Ohio suit are a who's-who of publicly traded cannabis. Ascend Wellness, headquartered in New Jersey. Trulieve Cannabis Corp., based in Tallahassee. Curaleaf Holdings, out of Connecticut. Green Thumb Industries, based in Chicago. Plus five more: Cresco Labs, Verano Holdings, Glass House Brands, Schwazze, and PharmaCann.

These aren't fly-by-night operations. Together, they represent the dominant share of regulated cannabis revenue in the United States. They're listed on Canadian exchanges. They have institutional investors. They have lobbyists. And, according to Ohio's AG, they have an arrangement.

The filing makes clear that Ohio believes this conduct extends far beyond its borders. Yost's complaint specifically references the same techniques being used in "other states, not just Ohio." Translation: every state with an MSO presence is potentially exposed. AGs in Pennsylvania, New Jersey, Illinois, Massachusetts, Maryland, and Florida are watching. Some are likely already drafting their own complaints.

Why "Cartel" Is Not Hyperbole

The word cartel does heavy lifting in the public imagination. People hear it and think of South American drug lords, of armed enforcers, of bodies in trunks. That's not what's being alleged here. What's being alleged is the corporate version, which is in some ways worse because it's done in suits, with lawyers, and with the explicit blessing of state regulators who looked the other way.

In economics, a cartel is simply an agreement among competitors to control supply, fix prices, or allocate markets. The Organization of the Petroleum Exporting Countries is a cartel. De Beers ran the diamond market as a cartel for nearly a century. The vitamin price-fixing cartel of the 1990s cost consumers billions before the Department of Justice broke it up.

What Ohio is alleging is structurally identical. Nine companies. Coordinated behavior. Restricted competition. Inflated prices. Market allocation. The fact that the product is cannabis instead of diamonds or vitamins doesn't change the legal analysis. It just changes who notices.

The Numbers Behind the Allegation

Cannabis prices in MSO-dominated states have not behaved like prices in a competitive market. In Ohio, wholesale prices for indoor flower remained stubbornly elevated through 2024 and 2025 even as cultivation capacity expanded — the opposite of what economic theory would predict in a functioning market. Retail markups in MSO-owned stores ran 40–60% higher than in adjacent states with more competitive structures.

Meanwhile, small Ohio operators reported being unable to land shelf placement at MSO-owned retail no matter what they offered. Pricing concessions, promotional support, exclusive cultivars — none of it moved the needle. The shelves were already spoken for.

This isn't unique to Ohio. The same pattern has played out in Pennsylvania, where five MSOs control the bulk of permitted retail. In Florida, where vertical integration requirements created a structural moat for early entrants. In New York, where the conditional adult-use rollout was supposed to favor justice-impacted entrepreneurs and instead created a parallel track for MSOs to dominate distribution.

What This Means for Independent Operators

If you're a craft cultivator, a social equity dispensary, or an independent brand trying to break into shelf space, the Ohio filing is the first piece of paper from a state government that validates what you've been experiencing. That has practical consequences.

It changes the negotiation. When an MSO retailer tells you they "can't" carry your product because of a corporate planogram, you now have a legal framework to argue that planogram itself may be unlawful. It opens up potential private antitrust claims under state laws that allow for treble damages.

It creates discovery exposure for the MSOs. Civil litigation that follows the AG's complaint will demand internal communications, pricing emails, executive calendars. Things people typed into Slack three years ago thinking nobody would ever read them are about to become court exhibits.

And it changes the calculus for retail buyers. A planogram chief at a multi-state retailer who was happy to take MSO-side incentives a year ago is going to think harder about it now that those same arrangements are being characterized as criminal in court filings.

What the MSOs Will Do Next

The defendants will move to dismiss. They will argue Ohio lacks jurisdiction, that the conduct is protected by various business-to-business privileges, that the harm to independent operators is speculative, that Yost is grandstanding for a future statewide political run.

Some of those arguments will have merit. Antitrust law is hard. Proving an actual agreement among competitors — as opposed to parallel conduct that just looks coordinated — requires either internal documents or witness testimony. Yost's office had to be confident in its evidentiary base before naming nine specific companies.

What we can predict: this is going to be slow. State antitrust litigation often runs three to five years from filing to verdict or settlement. The MSOs will appeal everything appealable. They will negotiate. They will settle quietly with conduct remedies and modest monetary penalties, the same way other corporate cartels eventually do.

But the damage to the industry's narrative is already done. The "professionalization" story — the one MSOs have told investors and regulators for a decade about how their scale and compliance discipline benefits consumers — is now contradicted on the record by a state attorney general. That's a permanent change to the discourse.

What Consumers Should Know

If you've been buying cannabis in an MSO-dominated state and wondering why an eighth costs $55 in Ohio when comparable product is $35 in Michigan or $25 in Maine, you now have part of the answer. Some of that price difference is taxation. Some is regulatory overhead. And some, according to the Ohio AG, is the predictable outcome of competitors deciding among themselves what the price will be.

You can't sue your way to lower prices as an individual consumer. But you can vote with your wallet. Independent dispensaries, when you can find them, generally carry independent brands. Social equity retailers, when they exist in your jurisdiction, deserve the support if their menus reflect their values. And the next time a politician in your state asks for industry input on cannabis policy, ask them whose input they actually mean.

The cartel allegations didn't come out of nowhere. They came from years of behavior that the people inside the industry watched happen in real time. Ohio is just the first state with the political will to put it on paper.

It will not be the last.

---

Cannabis.exposed is tracking every state action against MSOs as it develops. If you have direct knowledge of supply agreements, shelf-space allocation arrangements, or pricing coordination, contact our editorial team. We protect sources.

Internal links:

• The $1.6 Billion the MSOs Owe the IRS — And Why They're Not Paying →
• Curaleaf, Trulieve, Green Thumb: The MSOs Named in the Ohio Cartel Suit →
• The 12 MSOs That Control American Cannabis →